19094-Urothelial Cancer-NA-129

Urothelial Cancer

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Address

1800 Williams St, Suite 200
Denver, CO 80218
P: (303) 388-4876

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.